登赛珠单抗 T76788

Product Introduction
Bioactivity


英文名: Demcizumab

描述: Demcizumab (OMP 21M18) 是一种抗 DLL4 单克隆抗体。Demcizumab 是一种有效的 Notch 通路抑制剂。Demcizumab 在多种癌症模型中无论使单独还联合化疗试剂使用都是有效的。

体外活性: Demcizumab (0-100 μg/mL) binds to human DLL4 but not to mouse DLL4 and blocks the interaction of DLL4 with the Notch1 receptor in FACS binding assays[3].Following treatment with Demcizumab at 20 μg/mL for 48 hours, there is a reduction in the mRNA expression of HES1 and DTX1 in PDTALL cells[4].Demcizumab (0-80 μg/mL, 1, 2, or 3 days) promotes cell death and early apoptosis in PDTALL13 cells[4].

体内活性: Demcizumab (10 mg/kg, i.p., once weekly) in combination with Irinotecan (7.5 mg/kg) demonstrates a significant antitumor effect in KRASWT and KRASMT colorectal cancer xenograft models[2].Demcizumab, either alone or in combination with Irinotecan (7.5 mg/kg), is effective against OMP-C8 colon tumors[3].Administration of Demcizumab (20 mg/kg/week, intraperitoneal injection) increases the survival rate of NRG mice injected with irradiated PDTALL13 cells[4].

存储条件: store at low temperaturestore at -80°C

关键字: Demcizumab

相关产品: Avagacestat | CIA-1 hcl(452087-38-6 Free base) | FLI-06 | Aβ42-IN-2 | JI051 | Carvacrol | E 2012 | IMR-1A | 3,5-Bis(4-nitrophenoxy)benzoic acid | Ro 90-7501

登赛珠单抗 T76788信息由TargetMol中国为您提供，如您想了解更多关于登赛珠单抗 T76788报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途